TNYA Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
1.1M
+393.3%
225.0K
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
1.1M
+393.3%
225.0K
0
0
0
Operating Expenses
43.8M
+116.0%
20.3M
-2.3%
20.8M
-0.8%
20.9M
-13.1%
24.1M
R&D
16.6M
+11.9%
14.8M
+0.3%
14.8M
-3.7%
15.4M
-11.6%
17.4M
SG&A
5.4M
-0.8%
5.4M
-8.9%
6.0M
+7.2%
5.6M
-17.0%
6.7M
Operating Income
-42720000
-112.9%
-20065000
+3.4%
-20775000
+0.8%
-20936000
+13.1%
-24082000
EBITDA
-19201000
-4.9%
-18302000
+3.4%
-18948000
+0.7%
-19072000
+13.3%
-21998000
Net Income
-43393000
-125.2%
-19272000
+4.5%
-20175000
+0.5%
-20275000
+12.9%
-23283000
EPS (Basic)
$-0.20
-122.2%
$-0.09
+18.2%
$-0.11
+8.3%
$-0.12
+14.3%
$-0.14
EPS (Diluted)
$-0.20
-122.2%
$-0.09
+18.2%
$-0.11
+8.3%
$-0.12
+14.3%
$-0.14
Shares (Diluted)
217.6M
+0.3%
216.9M
+23.3%
175.9M
+7.7%
163.3M
+0.3%
162.8M
Tenaya Therapeutics (TNYA) โ€” Financials